Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Operations: 2013-2024

Historic Cash from Operations for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$391.2 million.

  • ImmunityBio's Cash from Operations rose 30.24% to -$68.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.7 million, marking a year-over-year increase of 24.12%. This contributed to the annual value of -$391.2 million for FY2024, which is 6.67% down from last year.
  • Latest data reveals that ImmunityBio reported Cash from Operations of -$391.2 million as of FY2024, which was down 6.67% from -$366.8 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Cash from Operations ranged from a high of -$171.7 million in FY2020 and a low of -$391.2 million during FY2024.
  • Over the past 3 years, ImmunityBio's median Cash from Operations value was -$366.8 million (recorded in 2023), while the average stood at -$365.2 million.
  • Data for ImmunityBio's Cash from Operations shows a maximum YoY plummeted of 59.80% (in 2021) over the last 5 years.
  • ImmunityBio's Cash from Operations (Yearly) stood at -$171.7 million in 2020, then plummeted by 59.80% to -$274.4 million in 2021, then decreased by 22.99% to -$337.5 million in 2022, then declined by 8.67% to -$366.8 million in 2023, then declined by 6.67% to -$391.2 million in 2024.